Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 108892
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108892
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108892
Ginsenoside F4 inhibits colorectal cancer progression by boosting dendritic cell maturation and remodeling the tumor microenvironment
Wei Xie, Xue-Jian Li, Yu-Sen Zhong, Jie Fang, Hua-Zhong Ying, Key Laboratory of Experimental Animal and Safety Evaluation, Hangzhou Medical College, Hangzhou 310013, Zhejiang Province, China
Wei Xie, Xue-Jian Li, Animal Research Center, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310053, Zhejiang Province, China
Hui Qi, Meng Yang, Department of Surgery, University of California, San Diego, CA 92037, United States
Chen-Huan Yu, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310022, Zhejiang Province, China
Co-corresponding authors: Hua-Zhong Ying and Chen-Huan Yu.
Author contributions: Ying HZ and Yu CH designed the research study; Xie W, Li XJ, Zhong YS and Fang J performed the research; Zhong YS, Fang J, Yang M and Qi H contributed new reagents and analytic tools; Xie W, Li XJ and Yu CH analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.
Supported by the Science and Technology Project of the Zhejiang Province, No. 2020Y.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Hangzhou Institute of Medicine, Chinese Academy of Sciences (No. 2023R01102).
Institutional animal care and use committee statement: The experiments were approved by the Animal Ethics Committee of Zhejiang Provincial Laboratory Animal Center (No. 2023R001099).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chen-Huan Yu, PhD, Dean, Senior Researcher, Hangzhou Institute of Medicine, Chinese Academy of Sciences, No. 150 Dongfang Street, Xiasha Sub-district, Qiantang District, Hangzhou 310022, Zhejiang Province, China. yuchenhuan2002@163.com
Received: April 27, 2025
Revised: June 4, 2025
Accepted: July 14, 2025
Published online: September 15, 2025
Processing time: 142 Days and 18.5 Hours
Revised: June 4, 2025
Accepted: July 14, 2025
Published online: September 15, 2025
Processing time: 142 Days and 18.5 Hours
Core Tip
Core Tip: This study provides novel insights into the antitumor effects of natural ginsenoside F4 on the apoptosis of colorectal cancer (CRC) cells by activating the sphingosine-1-phosphate 1-mediated phosphoinositide 3-kinase/protein kinase B and nuclear factor kappa-B pathways in dendritic cells, which subsequently triggers the antitumor effects of cluster of differentiation (CD)8+ T cells. Further investigation revealed that F4 inhibited tumor growth in CRC-bearing mice by recruiting dendritic cells and CD8+ T cells into the tumor immune microenvironment. These findings underscore the promising role of ginsenoside F4 in the management of CRC, highlighting the potential of natural ginsenosides as an adjuvant treatment for this disease.